Amrinone reduces ischaemia-reperfusion injury in rat heart

European Journal of Pharmacology

Volumn 402, Issue 3, 2000, Pages 255-262

  Rechtman, Mary P ^a   Van Der Zypp, Andrea ^b   Majewski, Henryk ^b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b RMIT UNIVERSITY   (Australia)

Author keywords

(Rat); Amrinone; Ischaemia; Reperfusion injury

Indexed keywords

AMRINONE; CALCIUM; CREATINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

1-METHYL-3-ISOBUTYLXANTHINE; 3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; AMRINONE; ANIMALS; CARDIOTONIC AGENTS; CREATINE KINASE; L-LACTATE DEHYDROGENASE; MALE; MILRINONE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 0034714377     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00443-X     Document Type: Article

References (29)

1. Alousi A.A., Johnson D.C. Pharmacology of the bipyridines: amrinone and milrinone. Circulation. 73:1986;III10-III24.
2. Alousi A.A., Stankus G.P., Stuart J.C., Walton L.H. Characterization of the cardiotonic effects of milrinone, a new potent cardiac bipyridine, on isolated tissues from several animal species. J. Cardiovasc. Pharmacol. 5:1983;804-811.
3. Beavo J.A., Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11:1990;150-155.
4. Buja L.M. Modulation of the myocardial response to ischaemia. Lab. Invest. 88:1998;1345-1373.
5. Cohen M.V., Yang X.M., Liu Y., Snell K.S., Doweney J.M. A new animal model of controlled coronary artery occlusion in conscious rabbits. Cardioavasc. Res. 28:1994;61-65.
6. Ferrari R. Metabolic disturbances during myocardial ischaemia and reperfusion. Am. J. Cardiol. 76:1995;17B-24B.
7. Garcia-Dorado D., Oliveras J. Myocardial oedema: a preventable cause of reperfusion injury? Cardiovasc. Res. 27:1993;1555-1563.
8. Hidaka H., Tanaka T., Itoh H. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases. Trends Pharmacol. Sci. 5:1984;237-239.
9. McVey M., Perrone M.H., Clark K.L. Does tumor necrosis factor-alpha (TNF-alpha) contribute to myocardial reperfusion injury in anaesthetised rats? Gen. Pharmacol. 32:1999;41-45.
10. 2+ uptake and cAMP in smooth muscle. Eur. J. Pharmacol. 61:1980;159-165.
11. Minatoguchi S., Majewski H. Milrinone inhibits sympathetically mediated tachycardia by a postjunctional action independent of cyclic AMP. J. Cardiovasc. Pharmacol. 18:1991;127-136.
12. Miura M. Regulation and failure of coronary circulation. Jpn. Heart J. 37:1996;585-602.
13. Murray K.J. Cyclic AMP and mechanisms of vasodilation. Pharmacol. Ther. 47:1990;329-345.
14. Nonami Y. The role of nitric oxide in cardiac ischemia-reperfusion injury. Jpn. Circ. J. 61:1997;119-132.
15. Opie L.H., Chatterjee K., Gersh B.J., Kaplan N.M., Marcus F.I., Poole-Wilson P., Singh B.N., Sonnenblick E.H., Thadani U. Drugs for the Heart. 3rd edn. 1991;Saunders, Philadelphia, PA.
16. Pang D.C. Tissues and species specificity of cardiac cAMP-phosphodiesterase inhibitors. Adv. Second Messenger Phosphoprotein Res. 25:1992;307-320.
17. Piper H.M., Garcia-Dorado D., Ovize M. A fresh look at reperfusion injury. Cardiovasc. Res. 38:1998;291-300.
18. Rump A.F., Blazincic B., Klaus W. Effect of amrinone and milrinone on myocardial ischaemia extent and infarct size in isolated rabbit hearts. Arzneimittelforschung. 43:1993;1262-1266.
19. Rump A.F., Rosen R., Sigmund B., Fuchs J., Dhein S., Klaus W. Beneficial effect of amrinone on the size of acute myocardial ischaemia in isolated rabbit hearts. J. Cardiothorac. Vasc. Anesth. 7:1993;573-578.
20. Rump A.F., Acar D., Klaus W. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. Br. J. Pharmacol. 112:1994;757-762.
21. Rump A.F., Schussler M., Acar D.et al. Effects of different inotropes with antioxidant properties on acute regional myocardial ischaemia in isolated rabbit hearts. Gen. Pharmacol. 26:1995;603-611.
22. Silver P.J., Hamel L.T., Perrone M.H., Bentley R.G., Bushover C.R., Evans D.B. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur. J. Pharmacol. 150:1988;85-94.
23. Silverman H.S., Stern M.D. Ionic basis of ischaemic cardiac injury: insights from cellular studies. Cardiovasc. Res. 28:1994;581-597.
24. Taira N. Inotropic agents: new positive inotropic agents and their mechanism of action. Rand M.J., Raper C. Pharmacology. 1987;477-480 Elsevier, Amsterdam.
25. Tejerina T., Sesin J., Delgado C., Tamargo J. Effect of milrinone on contractility and 45Ca movements in the isolated rabbit aorta. Eur. J. Pharmacol. 148:1988;239-246.
26. Triggle D.J., Rampe D. D1,4-Dihydropyridine activators and antagonists: structural and functional distinctions. Trends Pharmacol. Sci. 10:1989;507-511.
27. Van der Zypp A., Majewski H. Effect of cGMP inhibitors on the actions of nitrodilators in rat aorta. Clin. Exp. Pharmacol. Physiol. 25:1998;38-41.
28. Walsh M.P., Kargacin G.J., Kendrick-Jones J., Lincoln T.M. Intracellular mechanisms involved in the regulation of vascular smooth muscle tone. Can. J. Physiol. Pharmacol. 73:1995;565-573.
29. Woodman O.L. Modulation of vasoconstriction by endothelium-derived nitric oxide: the influence of vascular disease. Clin. Exp. Pharmacol. Physiol. 22:1995;585-593.